Finance Home - My Yahoo - Yahoo! - Help

Thursday, January 7, 2010, 9:13AM ET - U.S. Markets open in 17 mins.. Dow  0.02% Nasdaq  0.00%

Vertex Pharmaceuticals Incorporated (VRTX)

On Jan 6: 42.03   0.00 (0.00%)

MORE ON VRTX

Quotes Summary Real-Time Options Historical Prices Charts Interactive Basic Chart Basic Tech. Analysis News & Info Headlines Financial Blogs Company Events Message Board Company Profile Key Statistics SEC Filings Competitors Industry Components Analyst Coverage Analyst Opinion Analyst Estimates Research Reports Star Analysts Ownership Major Holders Insider Transactions Insider Roster Financials Income Statement Balance Sheet Cash Flow

Headlines Get Headlines for:
Change Display [ hide $$  edit ] Mon, Nov 2, 2009 • [video] Biopharma Barrage at CNBC (Mon, Nov 2) • Vertex Hep C Drug Emerges From Weekend Looking Stronger: BioBuzz at TheStreet.com (Mon, Nov 2) • Biotech Calendar: Key Dates for November at TheStreet.com (Mon, Nov 2) Sat, Oct 31, 2009 • Vertex Hep C Drug Cures 80% at New Dose: Study at TheStreet.com (Sat, Oct 31) • More than 80% of Hepatitis C Patients Treated in Study C208 Achieved an SVR with Telaprevir-Based Regimens Business Wire (Sat, Oct 31) Fri, Oct 30, 2009 • Vertex Pharmaceuticals Announces Webcast of its Presentations at Two Investor Conferences Business Wire (Fri, Oct 30) • Idenix down; Novartis won't license drug candidate AP (Fri, Oct 30) • Biotech Mailbag: The Reason(s) for This Selloff at TheStreet.com (Fri, Oct 30) Wed, Oct 28, 2009 • Vertex drug helps hepatitis C patients AP (Wed, Oct 28) • Vertex Hep C Drug Improves Cure Rates at TheStreet.com (Wed, Oct 28) • Vertex Hep C Drug Cures Hard-to-Treat Patients at TheStreet.com (Wed, Oct 28) • Interim Results from Study 107 Highlight the Potential Role of Telaprevir-Based Regimens in HCV Patients Who Failed Prior Treatment Business Wire (Wed, Oct 28) Tue, Oct 27, 2009 • Vertex's loss widens ahead of drug launch at bizjournals.com (Tue, Oct 27) Mon, Oct 26, 2009 • Earnings roundup: Heartland Financial, Masco AP (Mon, Oct 26) • Vertex loss grows on increased development costs AP (Mon, Oct 26) • VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen EDGAR Online (Mon, Oct 26) • Vertex Pharmaceuticals Reports Third Quarter 2009 Financial Results and Highlights Recent Business and Clinical Progress Business Wire (Mon, Oct 26) • Q3 2009 Vertex Pharmaceuticals Incorporated Earnings Release - After Market Close CCBN (Mon, Oct 26) Fri, Oct 23, 2009 • TradingMarkets 7 Stocks You Need to Know for Monday TradingMarkets.com (Fri, Oct 23) Tue, Oct 20, 2009 • AKT Inhibitor Moving Into Phase III Trials: Ladenburg Thalmann Sees This As Catalyst For Investors Wall Street Transcript (Tue, Oct 20) Wed, Oct 14, 2009 • Vertex Pharmaceuticals Announces the Date of its Third Quarter 2009 Financial Results Conference Call and Webcast Business Wire (Wed, Oct 14) Tue, Oct 6, 2009 • VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct EDGAR Online (Tue, Oct 6) Mon, Oct 5, 2009 • Investors Eye Vertex Hep C Competitor: BioBuzz at TheStreet.com (Mon, Oct 5) Fri, Oct 2, 2009 • A Plasma-tastic IPO at Motley Fool (Fri, Oct 2) Thu, Oct 1, 2009 • Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz at TheStreet.com (Thu, Oct 1) Older Headlines - Most Recent Headlines View headlines from: Thu, Oct 1, 2009Thu, Sep 24, 2009Thu, Sep 17, 2009Thu, Sep 10, 2009Thu, Sep 3, 2009Thu, Aug 27, 2009Thu, Aug 20, 2009Thu, Aug 13, 2009Thu, Aug 6, 2009Thu, Jul 30, 2009 Add VRTX News to My Yahoo!:
Add to Portfolio     Set Alert     Email to a Friend Get Headlines for Another Symbol: Symbol Lookup • Stocks In Play • Story Stocks • Full Coverage